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http://dx.doi.org/10.1016/j.ccr.2013.08.027SUMMARYMedullary thyroid carcinoma (MTC) is a neuroendocrine cancer that originates from calcitonin-secreting
parafollicular cells, or C cells. We found that Cdk5 and its cofactors p35 and p25 are highly expressed in hu-
manMTCand that Cdk5 activity promotesMTCproliferation. A conditionalMTCmousemodel was generated
and corroborated the role of aberrant Cdk5 activation in MTC. C cell-specific overexpression of p25 caused
rapid C cell hyperplasia leading to lethal MTC, which was arrested by repressing p25 overexpression. A
comparative phosphoproteomic screen between proliferating and arrested MTC identified the retinoblas-
toma protein (Rb) as a crucial Cdk5 downstream target. Prevention of Rb phosphorylation at Ser807/
Ser811 attenuated MTC proliferation. These findings implicate Cdk5 signaling via Rb as critical to MTC
tumorigenesis and progression.INTRODUCTION
Neuroendocrine tumors are relatively rare neoplasms character-
ized by abnormal hormone secretion, an indolent course, spe-
cific genetic mutations, and a poor response to conventional
therapies. Medullary thyroid carcinoma (MTC) arises fromC cells
and metastasizes frequently to regional lymph nodes, bones,
lungs, liver, and brain. Although MTC accounts for only 3–5%
of all thyroid cancers, it represents more than 14% of thyroid-
cancer-related deaths and affects both men and women, almost
equally (Massoll and Mazzaferri, 2004; Sippel et al., 2008).Significance
Neuroendocrine tumors are indolent malignancies arising from
MTC stems from the thyroid C cells and has a high mortality rat
rent primary therapy, but recurrence is common and more effe
motes human MTC proliferation and that transgenic induction
MTC. Furthermore, we reveal Rb protein as a downstream ef
Therefore, Cdk5 may be a promising drug target against MTC
CApproximately 25% of MTC cases are hereditary and occur as
familial MTC or as a component of the multiple endocrine
neoplasia 2 (MEN2) syndromes. MEN2A and MEN2B are auto-
somal-dominant syndromes in which MTC is frequently associ-
ated with pheochromocytoma (adrenal gland cancer). MEN2B
is the more severe form of the syndromes, and affected patients
develop additional symptoms such as mucosal neuromas and
marfanoid habitus. These genetic forms of MTC originate from
activating germline mutations in the rearranged during transfec-
tion (RET) proto-oncogene (Liska et al., 2005), which encodes a
tyrosine kinase receptor for the glial-derived neurotrophic factorhormone-producing cells scattered throughout the body.
e with rising incidence. Complete thyroid removal is the cur-
ctive treatments are needed. Here, we show that Cdk5 pro-
of aberrant Cdk5 activity in mouse thyroid C cells causes
fector by which Cdk5 drives neuroendocrine cell neoplasia.
.
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Cdk5 in Medullary Thyroid Carcinomafamily (GDNF; neurturin, artemin, and persephin) (Takahashi,
2001). Mechanisms by which RET mutations lead to MTC have
been extensively studied (Asai et al., 2006). However, the major-
ity of MTC cases (>75%) arise spontaneously, and only 40% of
these so-called sporadic cases are caused by somatic RET
mutations.
Themolecular basis of sporadicMTC is poorly understood (Hu
and Cote, 2012), although mutations in the RAS family of small
GTPase genes have recently been identified in RET-negative
MTC cases and RAS has been proposed to act as an alternative
driver to RET in MTC tumorigenesis (Agrawal et al., 2013; Boi-
chard et al., 2012; Ciampi et al., 2013). Consequently, therapeu-
tic strategies are limited (Schlumberger et al., 2008). Currently,
complete surgical removal of the thyroid remains the primary
treatment for early-stage MTC patients (Fialkowski and Moley,
2006). However, recurrence is common and metastases are
resistant to chemotherapy. The recent FDA approval of the tyro-
sine-kinase inhibitor Vandetanib provides a treatment option for
MTC (Wells et al., 2012). However, the use of this drug is limited
to unresectable, late-stage, and metastatic MTC and may pro-
duce unwanted side effects (Sherman, 2013). Thus, additional
therapies are needed and identifying novel molecular mecha-
nisms underlying MTC tumorigenesis is crucial for the develop-
ment of treatments for MTC.
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/
threonine kinase essential for the central nervous system devel-
opment and brain function (Angelo et al., 2006). Binding with its
noncyclin cofactors p35 and p39 activates Cdk5. Cellular stress
can induce the cleavage of p35 by the Ca2+-dependent protease
calpain to p25, which aberrantly activates Cdk5, thereby pro-
moting the phosphorylation of substrates implicated in neurode-
generation (Kusakawa et al., 2000). Cdk5’s functions beyond the
nervous system are still emerging. It modulates insulin secretion
in pancreatic b cells (Lilja et al., 2001; Wei et al., 2005) and may
contribute to cell cycle regulation and some forms of cancer
(Goodyear and Sharma, 2007; Jiang et al., 2005; Kim et al.,
2006; Lin et al., 2007; Lopes and Agostinho, 2011; Strock
et al., 2006). Indeed, elevated Cdk5 activity has been detected
in pancreatic and lung cancers (Demelash et al., 2012; Feldmann
et al., 2010). Furthermore, Cdk5 regulates motility and migration
of a variety of cancer cell lines, which suggests a role for Cdk5 in
tumor progression and metastasis (Huang et al., 2009; Quinta-
valle et al., 2011; Strock et al., 2006).
Neuroendocrine and neuronal cells both originate from the
neural crest and share common physiological features (Pang
and Su¨dhof, 2010). Given that Cdk5 plays a crucial role in
neuronal physiology, we hypothesized that Cdk5 also regulates
neuroendocrine cell function. Here, we investigate the role of
Cdk5 in human MTC tumorigenesis.
RESULTS
The Role of Cdk5 and Its Activators p35 and p25 in
Human MTC Proliferation
We detected Cdk5 in human thyroid gland and specifically in
neuroendocrine C cells as shown by colocalization of Cdk5
with calcitonin (Figures 1A and 1B). Expression of p35/p25 was
also evident in both follicular and C cells as detected by immu-
nostaining contiguous thyroid sections with a p35 antibody,500 Cancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc.which also detects p25 (Figure 1A; Figures S1A and S1B avail-
able online). Because neoplastic C cell hyperplasia is an early
step in the development of MTC, we examined Cdk5 and p35/
p25 expression in resected malignant specimens from 17 MTC
patients who underwent thyroidectomy. Cdk5 and p35/p25
expression was apparent in all MTC samples (Figures 1A, 1C,
and 1D; Figure S1A). Notably, Cdk5 and its activators were ex-
pressed at higher levels in sporadic MTC samples than in
noncancerous thyroid tissues (Figures 1C and 1D; Figure S1A).
Interestingly, Cdk5, p35, and p25 levels were not consistently
elevated in MEN2A specimens compared to control tissues,
suggesting possible mechanistic differences between at least
some hereditary and sporadic forms of this cancer (Figure 1D).
Furthermore, rising levels ofMTC (%neoplastic cellularity) corre-
lated with increasing p35/p25 expression in sporadic MTC
patient samples that were graded histopathologically (Figure 1E).
Altogether, these findings suggest that Cdk5 activity may be
important for human sporadic MTC tumorigenesis.
To investigate further the possible role of Cdk5 in MTC pro-
gression, we assessed Cdk5, p35, and p25 expression in a panel
of six human cell lines derived from sporadic MTC (Pfragner
et al., 2002). All MTC cell lines exhibited Cdk5 and p35 expres-
sion as well as p25 generation (Figure 2A). Because cultures of
normal human thyroid C cell cultures are difficult to establish
because of the low C cell content in a human thyroid biopsy
(1%), cultured normal human diploid fibroblasts (NDF) were
used as controls. NDF also exhibited p35 expression. However,
very little Cdk5 or p25 was detected in these cells. Treatment of
MTC cells with the Cdk5 inhibitor CP681301 (Karran and Palmer,
2007; Sadleir and Vassar, 2012; Wen et al., 2008) stopped their
proliferation and significantly reduced their viability (Figures 2B
and S2A). However, Cdk5 inhibition had little or no effect on
the proliferation and viability of NDF cells (Figure S2A). With
these positive results in hand, MTC-SK and SIN-J were selected
as representative for further analysis. MTC-SK cells were derived
from a solid sporadic MTC tumor, whereas SIN-J cells originated
from metastatic sporadic MTC (Pfragner et al., 1990; Pfragner
et al., 1993). Both have been characterized for their close similar-
ity to MTC tumor cells and express appreciable levels of Cdk5,
p35, and p25.
CP681301 is moderately selective for Cdk5 over Cdk2 in vitro
(2.8-fold). To confirm CP681301 specificity for Cdk5 over Cdk2,
we immunoprecipitated either Cdk5 or Cdk2 using cell lysates
from CP681301-treated MTC-SK and SIN-J cells and assessed
the activity of each kinase in vitro using histone H1 as a sub-
strate. Cdk5 but not Cdk2 activity was inhibited by CP681301
at the concentrations used in this study for both cell lines (Fig-
ure 2C; Figure S2B). Furthermore, competing with endogenous
Cdk5 activity by expressing a kinase-dead (KD) Cdk5 mutant
also reduced MTC-SK (Figure 2D) and SIN-J (Figure S2C) cell
proliferation. As for pharmacological inhibition, this reduction in
cell growth correlated with a reduction in Cdk5 activity in both
cell lines (Figure 2E; Figure S2D). Moreover, siRNA-mediated
knockdown of the Cdk5 activator p35 also reduced MTC-SK
and SIN-J cell growth (Figure 2F; Figure S2E). Again, p35 siRNA
significantly reduced Cdk5 activity in MTC-SK and SIN-J cells
without affecting Cdk2 activity (Figure 2G; Figure S2F). Together
these findings indicate that Cdk5 activity, as dictated by the
expression of its activating cofactors p35 and p25, is critical to
Figure 1. Cdk5 and Its Cofactors Are Expressed in Human Thyroid and in MTC
(A) Contiguous sections of normal human thyroid, sporadic medullary thyroid tumors, and hereditary medullary thyroid tumors (MEN2A syndrome) are immu-
nostained for calcitonin, Cdk5, and p35/p25. Scale bars are 20 mm for normal tissue stains and 100 mm for tumor stains (MEN2A, sporadic).
(B) High magnification image of normal thyroid costained for Cdk5 (brown) and calcitonin (dark blue) is shown. The arrow indicates C cell. Scale bar is 20 mm.
(C) Representative immunoblots of lysates from nonmalignant (Norm), sporadic (Spo), and familial (MEN2A) cancerous human thyroid specimens for Cdk5, p35/
p25, and GAPDH are shown.
(D) Quantification of (C) is shown. Each point represents the protein expression level normalized to the loading control for each sample. Horizontal bar lines
represent mean values for nonmalignant (n = 4–8), sporadic (n = 10–12), and MEN2A (n = 7). For Cdk5, Spo, p = 0.0048 andMEN2A, p = 0.4411; for p35, Spo, p =
0.0317 and MEN2A, p = 0.0793; for p25, Spo, p < 0.0001 and MEN2A, p = 0.2305 in a two-tailed unpaired Student’s t test with Welch’s correction. Vertical error
bars represent ± SEM.
(E) Immunoblots show the expression of Cdk5, p35, and p25 in samples of sporadic MTC patients at different stages of the disease and quantification. The
percentage of MTC cellularity was determined during the pathological analysis by quantifying microscopically the percentage of a representative slice that was
occupied by the MTC (see Supplemental Experimental Procedures). Values for each MTC sample were normalized to the loading control. Data represents mean
values of n = 1–8 samples as indicated. Error bars represent ± SEM.
See also Figure S1.
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Figure 2. MTC Cell Proliferation Is Dependent upon Cdk5 Activity
(A) Immunoblots of lysates from the indicated human sporadic MTC cell lines
and NDF probed with antibodies to Cdk5, p35, p25, and GAPDH are shown.
(B) Dose-dependent effect CP681301 on MTC-SK cell proliferation and
viability is shown.
(C) Effect of CP681301 on Cdk5 and Cdk2 activity is shown. Cdk5 and Cdk2
were immunopurified from MTC-SK cells treated with 0, 1, or 5 mM CP681301
for 12 hr and used to phosphorylate histone H1 in vitro. Immunoblots show
Cdk5 and Cdk2 used in immunoprecipitation-kinase assay reaction mixtures
(top). Kinase activity was detected by blotting for phospho-histone H1 (p-H1)
(middle). Coomassie-stained (CB) histone H1 controls show the amount of
substrate used in reactions (bottom). For quantitation of p-H1, for Cdk5
activity, p = 0.0037 for 0 versus 1 mM; p = 0.030 for 0 versus 5 mM.
(D) Immunoblots of lysates from MTC-SK cells transfected with a control
plasmid (Con) or with a KD-Cdk5 expression vector (KD) probed with anti-
bodies to Cdk5 and GAPDH (top) are shown; a histogram summarizing the
effect of Con or KD expression on cell proliferation (p = 0.0057) is shown
below.
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502 Cancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc.the proliferation of human sporadic MTC cells and may
contribute to some cases of MTC.
P25 Overexpression and Associated Cdk5 Activity
Result in Thyroid Tumor Formation
To delineate the effects of aberrant Cdk5 activation in MTC
tumorigenesis, we used the neuron-specific enolase (NSE) pro-
moter to drive GFP-tagged p25 overexpression (p25OE) in C
cells. In this bitransgenic mouse model, p25OE is regulated via
a tetracycline-controlled transactivator (tTA) system, which is
driven by the NSE promoter (Figure 3A) (Meyer et al., 2008). In
this model, p25OE can be induced by withdrawal of the tetracy-
cline analog doxycycline from the animal diet (Cruz et al., 2003),
while administration of doxycycline readily represses p25OE.
The p25OE mice developed large, bilateral thyroid tumors 16–
25 weeks after doxycycline removal (Figure 3B). These fast-
growing tumors were malignant as shown by FDG uptake during
PET imaging (Figures 3C and 3D). No p25OE mice survived past
30 weeks off doxycycline (Figure 3E). In contrast, control litter-
mates that lacked p25-GFP transgene had normal thyroids and
survival rates (Figures 3B and 3E). The tumors expressed high
levels of p25-GFP (Figures 3F and 3G) and were formed by calci-
tonin-positive neoplastic C cells that invaded the tracheal mus-
cle and extended into the tracheal lumen, leading to obstruction
(Figures 3H and 3I). Clusters of calcitonin-positive C cells
invaded and metastasized within the vasculature in the skeletal
muscles near the lungs (Figure 3J). Together these histological
analyses indicate that these thyroid tumors are MTC.
To monitor MTC tumorigenesis, thyroid samples were exam-
ined at different time points following induction of p25OE (Fig-
ure 4A). In control animals, thyroid gland was normal, comprised
of follicular cells surrounding distinct colloid-filled follicles. C
cells were interspersed in-between follicular cells as detected
by a calcitonin-specific immunostaining (Figure S3). After
5 weeks of p25OE, mild C cell hyperplasia developed and pro-
gressed into small tumors within 11 weeks. By 16 weeks, large
bilateral MTC tumors had formed and invaded the space be-
tween trachea and esophagus. At this stage, no more follicles
were visible. The thyroid tumors were divided by fibrous septa
in a nested pattern and consisted of a population of round cells
with uniform nuclei and amphophilic cytoplasm, characteristic of
MTC. All mice examined died within 30 weeks of p25OE. How-
ever, stopping p25OE after 5, 11, or 16 weeks led to 100% sur-
vival of mice analyzed for up to 32 weeks (Figure 4B). Indeed,(E) Immunoblots for p-H1 show Cdk5 and Cdk2 activity in MTC-SK cells
transfected with a control plasmid (Con) or with KD-Cdk5 (KD) (for Cdk5
activity, p = 0.0297). Immunoprecipitated Cdk5, Cdk2, and Coomassie-
stained histone H1 controls are shown.
(F) Immunoblots of lysates from MTC-SK cells transfected with a scrambled
siRNA (Con) or a p35 siRNA probed with antibodies to p35 and GAPDH (top);
below is a histogram summarizing the effect of Con or p35 siRNA expression
on cell proliferation (p = 0.0365).
(G) Immunoblots for p-H1 show Cdk5 and Cdk2 activity in MTC-SK cells
transfected with scrambled (Con) or p35 siRNA (for Cdk5 activity, p = 0.0178).
Immunoprecipitated Cdk5, Cdk2, and Coomassie-stained histone H1 controls
are shown.
All data represent mean values, error bars are ± SEM, and p values were
determined by a two-tailed paired Student’s t test, where n = 4 (C–G). For (B),
(D), and (G), number of cells is 1,000-fold. See also Figure S2.
Figure 3. Characterization of an MTC Ani-
mal Model
(A) Schematic of the bitransgenic system shows
activation of TetOp promoter-controlled p25-GFP
expression by doxycycline (Dox)-inhibitable tTa.
tTA expression is under NSE promoter control.
(B) Dissection shows the thyroid gland in p25OE
and control littermate. The arrow indicates tumors.
L, larynx; T, trachea.
(C) In vivo microPET/CT of WT thyroid versus
p25OE thyroid tumor (arrows) is shown. Repre-
sentative sagittal (top), coronal (middle), and
transaxial (bottom) images are shown.
(D) Time-dependent [18F]FDG uptake in thyroid
(WT) and thyroid tumors (p25OE) is shown. Mean
values are plotted. Error bars represent ± SEM
(n = 3).
(E) Survival curve for p25OE and control littermates
(n = 28) is shown.
(F) Optical fluorescent imaging of thyroid tumors
(arrow) in a p25OE mouse is shown.
(G) Immunoblots of thyroid (littermate control, Con)
versus p25OE thyroid tumor lysates for p25-GFP
(using anti-GFP antibodies) and GAPDH are
shown.
(H) Calcitonin staining (left; scale bar is 100 mm)
and GFP immunostaining (right; scale bar is
500 mm) of a p25OE tumor are shown.
(I) Representative hematoxylin and eosin (HE)
stainings (top) and corresponding calcitonin im-
munostains (bottom) of the thyroid and tracheal
region in a p25OE mouse are shown (scale bars
are 500 mm, top left; 200 mm, top and bottom right;
and 100 mm, bottom left). T, trachea; MTC, med-
ullary thyroid carcinoma.
(J) HE staining of metastatic C cells in skeletal
muscle vasculature (left; scale bar is 20 mm), and
HE staining (middle) and calcitonin immunostain
(right) of metastatic C cells within alveolar walls of
the lung (scale bar is 50 mm) of contiguous sections
are shown.
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(5 weeks) prevented C cell hyperplasia, while repressing
p25OE at later stages of the disease (11 or 16 weeks) resulted
in the arrest of tumor growth (Figure 4C). As expected, arrested
tumors lacked p25-GFP expression. However, repressing
p25OE did not affect Cdk5 or p35 protein levels (Figure 4D).
Cdk5 activity was significantly reduced in arrested (p25OE Off)
tumors compared to proliferating (p25OE On) tumors in which
p25 aberrantly activates Cdk5 (Figure 4E).
Together these results demonstrate that NSE promoter-driven
p25OE results in the formation of thyroid tumors featuring the
characteristics of human MTC (Fialkowski and Moley, 2006)
and that aberrant Cdk5 activation by p25-GFP contributes to
MTC proliferation in this mouse model.
In Vitro Characterization of p25OE Mice MTC
To further confirm the role of Cdk5 in MTC, we generated a cell
line from the MTC of p25OEmice (MTCp25). These cells grew as
floating clusters and exhibited anchorage-independent growth
and malignant transformation in a soft agar assay (Figure 5A).CImportantly, MTCp25 cells retained the characteristics of the
mouse tumors. These cells were calcitonin-positive, expressed
p25-GFP and Cdk5 (Figure 5B), and secreted calcitonin in the
culture media (approximately 100 pg/ml). As shown in the
tumors, p25-GFP expression and Cdk5 activity were controlled
by doxycycline (Figures 5C and 5D). Repressing p25-GFP over-
expression by culturing the cells in the presence of doxycycline
dose-dependently arrested cell proliferation but had no effect on
cell viability (Figure 5E). Furthermore, doxycycline had no effect
on the proliferation of a heterologous non-small-cell lung carci-
noma line, H1299 (Figure S4A). Thus, turning off p25OE with
doxycycline stops mouse MTCp25 cell growth without causing
cell death.
To substantiate the role of Cdk5 activity on MTC tumorigen-
esis, the effect of Cdk5 inhibition on MTCp25 cell proliferation
and viability was assessed. CP681301 dose-dependently
reduced MTCp25 cell proliferation and viability as was observed
with human MTC cell lines (Figure 5F). Moreover, two alternate
Cdk5 inhibitors, indolinone A and roscovitine, also stopped
MTCp25 cell proliferation (Figures S4B and S4C). Finally, siRNAancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc. 503
Figure 4. Progression and Arrest of MTC in p25OE Mice Is Controlled by p25 Expression and Associated Aberrant Cdk5 Activity
(A) HE staining of thyroid in control mice and mice with p25OE On for the indicated time period is shown. Scale bars are 100 mm.
(B) Schematic of p25OE On and Off with survival for each paradigm indicated (n = 4–7) is shown.
(C) Representative HE staining of typical thyroid for each paradigm of p25OE On followed by arrest (p25OE Off) is shown. Scale bars are 100 mm.
(D) Immunoblots of lysates from proliferating (p25OE On, 16 weeks) and arrested (p25OE On, 16 weeks, followed by p25 Off, 6 weeks) tumors (n = 4) for GFP-
tagged p25, p35, Cdk5, and GAPDH are shown. p25-GFP was detected by using either antibodies to GFP or antibodies to p35/p25.
(E) Immunoblot for p-H1 showing Cdk5 activity in proliferating ( Dox) and arrested (+ Dox) tumors as determined by immunoprecipitation/kinase assays using
histone H1 as a substrate is shown. Inhibition of Cdk5 by indolinone A, immunoprecipitated Cdk5, and Coomassie-stained (CB) histone H1 controls are shown.
See also Figure S3.
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well as cell growth (Figures 5G and 5H). Taken together, these
findings show that MTCp25 cell proliferation is dependent on
the Cdk5 activity that is mediated by p25OE, further supporting
a role for Cdk5 in MTC progression.504 Cancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc.Retinoblastoma Protein Plays a Critical Role
Downstream of Cdk5 Activation in MTC Proliferation
To identify Cdk5 downstream effectors, we profiled proteins
containing Cdk5 consensus phosphorylation sites in prolifer-
ating versus arrested p25OE mouse tumors by phospho-scan
Figure 5. Generation of a Mouse MTC Cell Line—MTCp25—That
Retains the Characteristics of p25OE Mice Tumors
(A) Brightfield and epifluorescent images show MTCp25 mouse cells growing
in suspension as cell clusters and colony formation in soft agar.
(B) Immunostaining of MTCp25 cells for Cdk5 (magenta), p25-GFP (yellow),
calcitonin (gray), and DAPI-stained nucleus (blue) are shown. Scale bar is
20 mm.
(C) Immunoblots of lysates from doxycycline-treated MTCp25 cells for p25
and Cdk5 show the effect of doxycycline on p25-GFP overexpression and on
Cdk5 expression.
(D) Immunoblot for p-H1 shows the effect of doxycycline on Cdk5 activity after
immunoprecipitating Cdk5 fromMTCp25 cells treated with doxycycline. Cdk5
inhibition by indolinone A, immunoprecipitated Cdk5, and Coomassie-stained
(CB) histone H1 controls are shown.
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Cliquid chromatography tandem mass spectrometry (Rush et al.,
2005). Peptides phosphorylated at serine 807 of Rb were highly
enriched in proliferating mouse tumors compared with arrested
tumors (Figure S5A), which was confirmed by immunoblotting
(Figure 6A). Likewise, phospho-Ser807/Ser811 Rb levels were
increased in doxycycline-deprived cultured MTCp25 cells in
which p25OE is induced andCdk5 activity is elevated (Figure 6B).
Furthermore, consistent with Cdk5, p35, and p25 expression,
phospho-Ser807/Ser811 Rb was elevated significantly in human
sporadic MTC tumors but not MEN2A samples compared to
control tissue (Figure 6C). Together, these results suggest a
mechanistic link between Cdk5 activity, Rb phosphorylation,
and sporadic MTC.
Because Ser807 and Ser811 are knownCdk5 phosphorylation
sites (Futatsugi et al., 2012; Hamdane et al., 2005) and Rb dele-
tion has been linked to neuroendocrine tumorigenesis (Takaha-
shi et al., 2006; Williams et al., 1994), we postulated that Rb is
a downstream effector of Cdk5 and that Cdk5-Rb signaling
promotes MTC. Indeed, inhibiting Cdk5 activity in mouse and
human MTC cells by treatment with CP681301 decreased phos-
pho-Ser807/Ser811 Rb in a dose-dependent manner and
stopped cell growth (Figures 6D and 6E; Figure S5B; Figure 2B;
Figure S2A). Furthermore, disrupting Cdk5 activity in human
MTC cells by expressing a kinase-dead Cdk5 or knockdown of
p35 diminished phospho-Ser807/Ser811 Rb and reduced MTC
cell proliferation (Figures 6F and 6G; Figures 2D and 2F; Figures
S5C, S5D, S2C, and S2E). Finally, competing with Cdk5 phos-
phorylation of Rb by treating mouse or human MTC cell lines
with a small inhibiting peptide (SIP) that consisted of a
19-amino-acid Rb sequence encompassing Ser807/Ser811
dose-dependently reduced phospho-Ser807/Ser811 Rb and
cell proliferation (Figure 6H; Figure S5E). The SIP had no effect
on STAT3 phosphorylation at knownCdk5 sites, indicating spec-
ificity for Rb phosphorylation (Figure 6H). Together, these find-
ings identify Rb as a Cdk5 downstream target in MTC
tumorigenesis.
Having confirmed Rb as an important Cdk5 target, we investi-
gated the mechanism by which Cdk5-Rb mediates MTC pro-
liferation. Rb acts as a tumor suppressor by binding the E2F
transcription factors, thereby blocking their transcriptional activ-
ity. Upon Rb phosphorylation by cyclin-dependent kinases,
E2Fs are released and activate the expression of their target
genes, including Cdk2 and Cyclin A (Chellappan et al., 1991; De-
Gregori et al., 1997; Knudsen et al., 1999). In agreement with this,
arrest of mouse tumor growth by repressing p25OE abolished
Cdk2 and Cyclin A expression (Figure 6I). Furthermore, inhibiting
Cdk5 activity in human MTC cells with CP681301 attenuated(E and F) Dose-dependent effect of doxycyline (E) and CP681301 (F) on
MTCp25 cell proliferation and viability is shown.
(G) Immunoblots of lysates from MTCp25 cells transfected with a scrambled
siRNA (Con) or a Cdk5 siRNA (siRNA) probed with antibodies to Cdk5 and
GAPDH (top) are shown; the histogram summarizes the effect of Con or Cdk5
siRNA expression on cell proliferation (p = 0.023) (bottom).
(H) Immunoblot for p-H1 shows immunoprecipitated Cdk5 activity in cells
transfected with Cdk5 siRNA and quantification (p = 0.0145). Immunoprecip-
itated Cdk5 and Coomassie-stained (CB) histone H1 controls are shown.
All data represent mean values (n = 4) and error bars are ± SEM; p values were
determined by a two-tailed paired Student’s t test. For (E), (F), and (G), cell
numbers are 1,000-fold. See also Figure S4.
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Figure 6. Rb Is a Downstream Target of Cdk5 in MTC
(A) Immunoblots of lysates fromproliferating (p25OEOn) and arrested (p25OEOff) p25OE tumors probedwith antibodies to phospho-Ser807/Ser811 (pS-Rb) and
total Rb (n = 4) are shown.
(B) Effect of doxycycline-induced repression on pS-Rb levels in MTCp25 cells is shown.
(C) Immunoblots of lysates from normal thyroid (Norm) (n = 5), sporadic (Spo) (n = 6), and hereditary (MEN2A) (n = 7) MTC patient specimens were probed with
antibodies to pS-Rb and GAPDH. For Spo, p = 0.0117; MEN2A, p = 0.1316, two-tailed unpaired Student’s t test with Welch’s correction.
(D and E) Immunoblots of lysates fromMTCp25 cells (D) andMTC-SK cells (E) following a 16 hr CP681301 treatment probedwith antibodies to pS-Rb andGAPDH
and quantification are shown.
(F and G) Immunoblots from lysates of MTC-SK cells transfected with (F) a control plasmid (Con) or a kinase-dead Cdk5 expression vector (KD) and (G) with a
scrambled siRNA (Con) or a p35 siRNA (siRNA) and probed with antibodies to pS-Rb and GAPDH and quantification are shown. In (F), p = 0.0057; in (G) p =
0.0365.
(H) Immunoblots show the effect of SIP on the phosphorylation of endogenous Rb (at Ser807/Ser811) and STAT3 (left panel). Effect of 10 mMRb SIP on MTCp25
(left) and MTC-SK (right) cell proliferation is shown (right panel). For MTCp25, p = 0.0336; for MTC-SK, p = 0.0157.
(I) Immunoblots of lysates from proliferating (p25OE On) and arrested (p25OE Off) mouse tumors probed with antibodies to pS-Rb, Cdk2, Cyclin A, and GAPDH
are shown.
(J) Immunoblots of lysates from MTC-SK cells treated with CP681301 (5 mM) for 0, 12, or 24 hr probed with antibodies to pS-Rb, Cdk2, Cyclin A, Cdk5, and
GAPDH and quantification are shown. For pS-Rb, p < 0.0001 for 0 versus 12 hr, and p < 0.0002 for 0 versus 24 hr; for Cdk2, p = 0.0315 for 0 versus 12 hr, and p =
0.0104 for 0 versus 24 hr; for Cyclin A, p = 0.0257 for 0 versus 24 hr.
(legend continued on next page)
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12 hr and by 40% after 24 hr of treatment (Figure 6J). In SIN-J
cells, CP681301 reduced Cdk2 and Cyclin A levels by more
than 50% within 12 hr (Figure S5F). As expected, Rb phosphor-
ylation levels were reduced by more than 50% within 12 hr
following CP681301 application to both cell lines. Thus, Cdk2
and Cyclin A appear to be invoked as downstream effectors of
the Cdk5-Rb signaling and this cascade may mediate MTC
tumorigenesis. In line with these observations, MTC cell growth
was reduced by pharmacological blockade of Cdk2 activity with
CVT-313 (Figure 6K; Figure S5G). Importantly, inhibition of Cdk2
only partially reduced Rb phosphorylation but had no effect on
Cdk5 expression and activity (Figures 6L and 6M; Figure S5H).
This effect is consistent with the ability of Cdk2 to contribute to
Rb phosphorylation and cell cycle progression (Harbour et al.,
1999). Thus, Cdk5 may contribute meaningfully to the progres-
sion of some forms of MTC by inactivating Rb and enabling the
expression of the E2F target genes, Cdk2 and Cyclin A
(Figure 6N).
DISCUSSION
Although tremendous advances have been made in under-
standing how RET causes MTC, little is known about other
mechanisms that contribute to the majority of neuroendocrine
thyroid cancers. Here, we demonstrate that Cdk5 is crucial for
human MTC cell proliferation and thus it contributes to MTC
progression. Previous work implicated Cdk5/p35 in the prolifer-
ation of the TT cell line, which was derived from familial human
MTC and contains a RET mutation at codon 634 resulting in
constitutive RET activation (Berger et al., 1984; Lin et al.,
2007). It was suggested that p35, but not p25, drives Cdk5
activity and is necessary to maintain the RET-dependent growth
of this cell line, implying that Cdk5 activation may be down-
stream of RET. However we found that dysregulation of Cdk5
activity by overexpressing p25 caused MTC, thus suggesting
that Cdk5 rather than RET may trigger MTC. Nevertheless, a
link between Cdk5 activity in human MTC and the RET or
RAS signaling pathways cannot be ruled out and should be
further explored.
In evaluating pro-proliferative downstream effectors for Cdk5,
we found that Cdk5 phosphorylates Rb and that inactivation of
Cdk5 prevents Rb phosphorylation and reduces Cdk2 and
Cyclin A expression in human MTC cells and arrested mouse
tumors. Deregulation of Rb signaling is a well-known cause of
cancer (Weinberg, 1995). Rb is a tumor suppressor that prevents
cell cycle progression from G1 to S by binding and sequestering
E2F transcription factors (Sellers et al., 1995). Upon Rb phos-
phorylation by cyclin/cyclin-dependent kinase complexes,
E2Fs are released and activate the transcription of target genes(K) Effect of CVT-313 on sporadic MTC-SK cell proliferation and viability is show
(L) Immunoblots of lysates from MTC-SK cells treated with CVT-313 for 12–14 h
(M) Immunoblot for p-H1 showing Cdk2 and Cdk5 activity in MTC-SK cells treat
(N) A schematic model for the Cdk5-Rb-Cdk2 pathway in MTC is shown. Rb bi
proliferation. Upon Rb phosphorylation by Cdk5, E2F is released and activates t
proliferation.
All data are mean values (n = 4) and error bars represent ± SEM; p values were det
1,000-fold. See also Figure S5.
Cwhose products are necessary for cell cycle progression
(Bracken et al., 2004). Numerousmitogenic and oncogenic path-
ways invoke Cyclin D expression. The resulting Cyclin D-Cdk4/
Cdk6 complexes catalyze the initial Rb phosphorylation while
Cyclin A-Cdk2 can contribute to the maintenance of the phos-
pho-Rb-dependent neoplastic state (Nevins, 2001). Our findings
raise the possibility that Cdk5 may catalyze the initial Rb phos-
phorylation and replace Cyclin D-Cdk4/Cdk6 complexes in
some neuroendocrine cancers.
In support of this hypothesis, here Rb phosphorylation at
Ser807/Ser811 correlated with Cdk5 activity in growing mouse
tumors and in human MTC cells and was arrested in MTC cells
overexpressing dominant negative, kinase-dead Cdk5 or sub-
jected to p35 knockdown. Previously, Ser807/Ser811 Rb was
reported as a substrate of aberrant Cdk5 in injured neurons (Pan-
ickar et al., 2008). The present results implicate Rb as a likely
Cdk5 substrate in MTC tumorigenesis. Given that Cdk5 plays
important roles in the central nervous system, using a Cdk5
inhibitor to treat MTCmay have undesirable side effects. Target-
ing protein-protein interactions such as those of Rb or other pro-
proliferative downstream effectors may provide more selectivity
for eventual clinical applications.
Previously, loss of Rb and E2F transcription factors alleles has
been linked to neuroendocrine cancers including MTC (Salon
et al., 2007; Takahashi et al., 2004; Ziebold et al., 2003). For
example, mice carrying a single functional copy of the Rb wild-
type gene develop MTC and this tendency is increased in the
C57BL6 mouse strain (Harrison et al., 1995; Leung et al., 2004;
Nikitin et al., 1999; Williams et al., 1994; Yamasaki et al., 1998).
In humans, genetic analysis of sporadic and hereditary MTC
patients has identified mutations in genes encoding the INK4
and CIP/KIP families of CDK inhibitors, which are negative regu-
lators of the Rb pathway. Specifically, somatic mutations in the
CDKN2C gene (p18INK4 gene) have been found in several studies
and correlated to higher MTC proliferation rates (Flicker et al.,
2012; van Veelen et al., 2009). Additionally, mutations within
chromosome 19p13.2, which contains the CDKN2D gene
(p19INK4D gene), have also been detected frequently in MTC
patients (Flicker et al., 2012; Ye et al., 2008). Finally, theCDKN2B
gene (p15INK4 gene) has been identified as a low-penetrance
gene in MTC (Ruiz-Llorente et al., 2007). Thus, these genetic
analyses provide ample evidence that, in addition to RET/RAS
somatic mutations, targeting of the Rb pathways through inacti-
vation of CDK inhibitor family members contributes to human
MTC tumorigenesis.
In our mouse model, NSE promoter-driven p25-GFP expres-
sion was predominantly detected in the thyroid. Only low levels
of p25-GFP could be detected in lungs and adrenal gland, and
no primary tumors were observed in these tissues. The reason
for this expression selectivity or possible sensitivity of C cellsn.
r probed with antibodies to pS-Rb, Cdk5, and GAPDH are shown.
ed with CVT-313 for 12–14 hr. For Cdk2, p = 0.0051 for 0 versus 25 mM.
nds to E2F and suppresses its transcriptional activity, thereby preventing cell
he transcription of target genes including Cdk2 and Cyclin A that mediate cell
ermined by a two-tailed paired Student’s t test. For (H) and (K), cell numbers are
ancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc. 507
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exclude a role for Cdk5 in other neuroendocrine cancers.
Neuroendocrine cancers are silent killers because they are
difficult to diagnose due to a lack of symptoms and are often un-
covered at advanced stages when the window for effective sur-
gical treatment has passed. Few treatment options are available
in part as a result of incomplete understanding of the underlying
molecular pathways and the lack of relevant animal models
(Knostman et al., 2007). Existing models of MTC include trans-
genic mice bearing RET mutations (Cranston and Ponder,
2003) and animals deficient for Rb1/p53 (Harvey et al., 1995),
prolactin receptor (Kedzia et al., 2005), or Rb1/Nras (Takahashi
et al., 2006). However in most of these, constitutive transgene
expression or gene knockout may introduce congenital con-
founds. In the model introduced here, MTC is reversibly and
reproducibly induced in an adult with a fully developed and func-
tional thyroid. Importantly, MTC originates from p25-mediated
aberrant Cdk5 activation in C cells and not from a RET mutation.
Hence, the animal model established here represents a clinically
relevant model to study the onset and progression of sporadic
MTC carcinogenesis. Furthermore, the ability to arrest the dis-
ease at various stages may facilitate the identification of drug-
gable targets for therapy development. Finally, thismousemodel
will be a useful preclinical tool for the development and testing of
new adjuvant therapies for MTC (Dar et al., 2012; Wells et al.,
2012).
EXPERIMENTAL PROCEDURES
Antibodies, siRNAs, Plasmids, and Peptides
Antibodies for human calcitonin were from DAKO; GFP from Abcam; GADPH
from Sigma; and Cdk5, Cdk2, Cyclin A, and p35/p25 from Santa Cruz Biotech-
nology. The Cdk5 monoclonal Ab was described by Lagace et al. (2008). The
p35/p25 polyclonal antibody is directed to an antigen in the C terminus of p35
and does not distinguish between p35 and p25. The specificity of p35/p25
antibody has been verified in brain tissues of p35 knockout animals (Fig-
ure S1B). Antibodies to total Rb, pRb-Ser807/Ser811, STAT3, and pSTAT3
were from Cell Signaling Technology, and phospho-histone H1 from Millipore.
Cdk5 siRNA was from Santa Cruz Biotechnology and p35 siRNA from Sigma.
The kinase-dead CDK5 construct pCMV-KD-Cdk5 was previously described
(Saito et al., 2007), and the pCMV-EGFP was from Clontech. The peptide
was synthesized by the UT Southwestern Protein Chemistry Technology Cen-
ter. The sequence of the Rb-Cdk5 small interfering peptide (SIP) was R7-
PGGNIYISPLKSPYKISEGL and the control peptide R7-SYFHKEDRPPRDK.
Human Tissue Samples
Normal human and medullary thyroid specimens were obtained through a
human subject institutional-review-board-approved protocol UT South-
western IRB 052004-044, ‘‘Molecular Analysis of Endocrine Tumors.’’ Written
consent of subjects was obtained. Diagnosis of the neoplasm was confirmed
by pathological review, and RET-germline mutation analyses were obtained
fromMTC patient records. All MEN2A samples harbored germline point muta-
tion in RET codon 634 resulting from a cysteine to tyrosine substitution.
Generation of NSE TetOp p25-GFP Mice
Bitransgenic mice were generated as described previously (Meyer et al.,
2008). Briefly, the p25-GFP340 mouse strain, which contains a human p25-
GFP transgene driven by the TetOp promoter (TetOp-p25-GFP), was crossed
with the NSE5021 strain, which has a tetracycline transactivator (tTA) directed
by the neural-specific enolase promoter (NSE). This form of p25 is functional
(Cruz et al., 2003) and the use of the TetOp system to drive NSE-directed
expression has been well characterized (Chen et al., 1998).
All mouse strains were maintained on a C57BL/6 background. Transgenic
alleles were identified by a PCR-based genotyping strategy for p25-GFP and508 Cancer Cell 24, 499–511, October 14, 2013 ª2013 Elsevier Inc.NSE-tTA alleles. Bitransgenic p25OE mice were positive for the NSE-tTA and
p25-GFP transgenes. Control littermates were positive for NSE-tTA but not
p25-GFP. Both groups were treated identically with regard to doxycycline
administration. All subjects used in these studies were group-housed on a
12 hr light/dark cycle with access to food and water ad libitum. All procedures
were performed during the light cycle between 0600 and 1800, were
approved by the Institutional Animal Care and Use Committee of the Univer-
sity of Texas, and conducted in accordance with the applicable portions of
the National Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Cell Culture, Transfections, Drugs, and SIP Treatment
SHER-I, GRS-V, GRS-IV, RARE, SIN-J, and MTC-SK cell lines were derived
from human sporadic MTC tumors and maintained as described (Kaczirek
et al., 2004; Pfragner et al., 1990, 2002). The MTCp25 mouse line was estab-
lished by using MTC from mice that were overexpressing p25-GFP for at least
16 weeks. Normal human diploid fibroblasts were obtained from dissected
mammary tissue using routine procedures. Cells were cultured in DMEM con-
taining 10% FBS and were employed at passage 4. For drug treatments and
small interfering peptide (SIP) assays, MTCp25 cells and each human cell
line were plated at a density of 2 3 105 cells/ml and incubated with different
concentrations of doxycycline, CP681301, indolinone A, roscovitine, and SIP
for up to 5 days. The SIP contained an N-terminal poly-arginine (R7) tag to
penetrate the cell. Standard methods were used for transfections and soft
agar assays. Detailed procedures can be found in the Supplemental Experi-
mental Procedures.
Cell Proliferation and Viability Assays
For proliferation analysis, cells were plated at a density of 23 105 cells/ml. The
number of cells was determined on various days after plating by using a CASY-
1 Cell Counter and Analyzer TTC (Scha¨rfe System). In the figures, ‘‘number of
cells’’ refers to the total number of cells that are counted in 1 ml cell suspen-
sion. Thus, the number of cells includes alive and dead cells. For cell viability
assays, WST-1 Cell Proliferation Reagent (4-[3-(4-iodophenyl)-2-(4-nitro-
phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) (Roche Diagnostics) was
used as per the manufacturer’s instructions. Assays were performed in tripli-
cate and repeated at least two times.
Immunoprecipitation-Kinase Assay
Proliferating mouse tumors were collected from mice deprived of doxycycline
for at least 16 weeks. Arrested mouse tumors were obtained from mice that
were off doxycycline for 16 weeks and replaced on doxycyline for 4 more
weeks. MTCp25 cells were plated at a density of 2 3 105 cells/ml and
treated, or not, with 10 mM doxycycline for 4 days. MTC-SK and SIN-J cells
were plated at a density of 3 3 105 cells/ml and treated for 12 hr with
CP681301 or transfected with pCMV-KD-Cdk5 or p35 siRNA. Transfected
cells were harvested 24 hr (pCMV-KD-Cdk5) or 5 days (p35 siRNA) post
transfection. Cdk5 or Cdk2 were immunoprecipitated from cell lysates by
using anti-Cdk5 or anti-Cdk2 antibodies, and their activity was assessed
in vitro in saturating enzyme conditions and using histone H1 as a substrate.
Detailed procedures can be found in the Supplemental Experimental
Procedures.
Immunoblotting
Immunoblotting was carried out as previously described (Bibb et al., 1999).
Statistical Analysis
Data for individual assays represent themean ± SEM. All experimentswere de-
signed with matched control conditions within each experiment to enable sta-
tistical comparison via two-tailed Student’s t test, and all p values <0.05 were
considered statistically significant. GraphPad Prism 6.0 was used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.08.027.
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